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ABSTRACT Antigen HLA-B27 is a high-risk genetic fac-
tor with respect to a group of rheumatoid disorders, especially
ankylosing spondylitis. A cDNA library was constructed from
an autozygous B-cell line expressing HLA-B27, HLA-Cwl, and
the previously cloned HLA-A2 antigen. Clones detected with an
HLA probe' were isolated and sorted into homology groups by
differential hybridization and restriction maps. Nucleotide
sequencing allowed the unambiguous assignment of cDNAs to
HL4-A, -B, and -C loci. The HLA-B27 mRNA has the
structural features and the codon variability typical of an HLA
class I transcript but it specifies two uncommon amino acid
replacements: a cysteine in position 67 and a serine in position
131. The latter substitution may have functional consequences,
because it occurs in a conserved region and at a position
invariably occupied by a species-specific arginine in humans
and lysine in mice. The availability of the complete sequence of
HLA-B27 and of the partial sequence of HLA-Cwl allows the
recognition of locus-specific sequence markers, particularly,
but not exclusively, in the transmembrane and cytoplasmic
domains.
The HLA-A, -B, and -C (class I) antigens are integral
membrane proteins composed of two noncovalently associ-
ated molecules: a highly polymorphic glycosylated heavy
chain (44 kDa) encoded in the major histocompatibility
complex (MHC) on chromosome 6 and the invariant 82-
microglobulin polypeptide (12 kDa) encoded on chromosome
15. These antigens are expressed essentially on all nucleated
cells and have the role of restricting recognition by cytotoxic
T lymphocytes oftissue allografts and virus-infected cells (for
review, see ref. 1). Moreover, the human MHC markers have
additional biological and epidemiological relevance, because
a number of diseases. are known to be associated with HLA
(reviewed in ref. 2). Although most ofthe illnesses previously
found associated with class I markers and characterized by
immunological overtones have later been resolved into two
major groups that correlate more strongly with HLA class II
and class III genes, the class I antigen HLA-B27 remains a
striking exception (3). The case of this antigen is also very
notable owing to the unusually high risk that HLA-B27-
positive individuals have of contracting various forms of
rheumatoid disorders, among which ankylosing spondylitis
(AS) predominates. The strong association of this disease in
various ethnic groups with HLA-B27 [and not with other
genes of the HLA complex (3)], the apparent dominant mode
of inheritance of AS (4, 5), and the finding that HLA-B27
crossreacts with epitopes found on bacteria implicated in the
course of the disease (2) provide the main evidence support-
ing a direct etiological contribution of this polymorphic
marker to the pathogenesis of the disorder. However, other
authors (cf. refs. 4, 5) interpret the lack of an absolute
epidemiological association as evidence for the existence of
a distinct "illness susceptibility" gene and regard the HLA
marker as an incidental indicator of the mutant due to locus
polymorphism and linkage disequilibrium. We sought to
determine the complete sequence of an HLA-B27 mRNA as
a direct approach to the primary structure of the antigen and
to the nucleotide information necessary for the search at the
genomic level of the putative "illness" locus. The choice of
this approach was also dictated by an interest in obtaining the
molecular tools for testing the basis of the crossreactivity of
anti-HLA-B27 antibodies with certain bacterial cell walls.
MATERIALS AND METHODS
RecombinantcDNA clones were prepared from size-selected
mRNA isolated from the autozygous B-cell line LG-2 (6)
established from individual V.I. of the inbred family STA (7).
Synthesis, size selection, and insertion of double-stranded
cDNA by dG-dC homopolymer tailing in the Pst I site of
pBR322 used for transformation of Escherichia coli strain
C600 were essentially according to standard protocols (8).
RESULTS
Detection and Grouping of HLA Class I-Encoding cDNA
Clones. The approach utilized for the isolation of HLA-B27
cDNA clones involved the preparation of a cI)NA library
from a cell line autozygous for the HLA' antigens A2, B27,
and Cwl. It was anticipated that the selection of a genotype
carrying an HLA-A allele whose sequence was known (9) and
the availability of the HLA-B7 (10) and the HLA-Cw3 (11)
sequences would ease the identification of the sought cDNA.
Clones encoding the HLA class I antigens were detected by
hybridization with an HLA full-length cDNA probe (10, 12).
As studies in the murine (13) and human (14) systems have
shown that sequences from the 3' untranslated part (3' UT)
can be used for the identification of certain individual class I
genes, we attempted.to group-the cDNA clones of the LG-2
cell line by means of two such described probes (14). Of 40
class I-positive clones, 8 gave a stronger signal with the
HLA-B-specific probe (no. 2 in Fig. 1) and 12 gave a stronger
signal with the HLA-A-specific probe (no. 3 in Fig. 1). Clones
displaying weak hybridization signals probably contain. in-
sertions covered only partially by the two probes' or they
represent sequences less closely related to the HLA-A and -B
genes. Indeed, in contrast to the relative homogeneity found
within the putative HLA-A and HLA-B cDNA groups (Fig.
Abbreviations: AS, ankylosing spondylitis; bp, base pair(s); MHC,
major histocompatibility complex; 3' UT, 3' untranslated part.
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FIG. 1. Detection and locus assortment of HLA class I cDNA
clones. Clones were detected by colony hybridization (washes were
done at least twice in 0.15 M NaCl/0.015 M trisodium citrate at 650C)
and classified by the probes indicated: probe 1, pHLA-2 (10, 12);
probe 2, pHLA-1.1, HLA-B specific (14, 15); probe 3, pHLA 2a.1,
HLA-A specific (14). The HLA-A and -B groupings found by
differential hybridization were confirmed by the restriction enzyme
sites shown: K, Kpn I; P, Pst I; V, Pvu H. The segmentation denotes
domains 1-3 and the transmembrane and the cytoplasmic region of
the protein, followed by the 3' UT of the mRNA.
1), a restriction map analysis showed that the third group
includes different kinds of transcripts, one of which (clone
pC1) attracted our attention for the unexpected presence of
sites diagnostic of the HLA-B group.
Identification and Characterization of HLA-B27 and HLA-
Cwl cDNA Clones. Partial sequencing (data not shown) of
clones from the putative HLA-A group definitely identified
them as transcripts of the HLA-A2 gene (16) in accordance
with the genotype of the cell line. Thus, to detect an
HLA-B27-specific cDNA clone we focused on the second
group of plasmids (pB1-4) and on clone pC1 (Fig. 2). The
nucleotide sequence comparisons reported in Fig. 3 show
that clone pC1 carries an HLA-C-related sequence and that
the pB set of clones encodes a sequence strongly homologous
to HLA-B7. On the basis of the phenotype of the autozygous
cell line we conclude that clone pC1 encodes part of the
antigen HLA-Cwl, whereas the sequence identified by the
series of pB clones specifies the antigen HLA-B27. The
nucleotide sequence merged from the two overlapping clones
pBl [1372 base pairs (bp)] and pB3 (605 bp) spans the entire
coding region and the 3' UT end of an HLA-B27 mRNA. The
overall features of this transcript are those typical of a class
I heavy chain mRNA. Clone pB3 encodes 21 amino acids of
the signal peptide and terminates prior to the ATG starting
codon, which for the known HLA class I gene sequences is
located several base pairs upstream (11, 16, 19). A translation
termination codon was found at the end of the fourth exon
(corresponding to triplet 274 in Fig. 3) of clone pB1. How-
ever, two additional clones, pB2 and pB4, showed a TGG
codon in this position. Furthermore, no evidence could be
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FIG. 2. Sequencing strategies. cDNA fiagments shown were
subcloned and sequenced by the dideoxy method (17); an ambiguous
stretch (MG) in clone pB1 was verified by the Maxam and Gilbert
protocol (18). Restriction sites are shown in relation to the exons of
a typical HLA heavy chain including the 3' UT region. A, Sau3A; B,
Bgl I; G, Bgi II; H, Hinfl; K, Kpn I; P, Pst I; S, Sac I; T, Taq I; V,
PVU II.
found for the expression of a truncated HLA polypeptide
either by in vitro translation of hybrid-selected mRNA or by
immunoprecipitations of metabolically labeled cell products
(data not shown). Considering also that the reverse
transcriptase used for the synthesis of both cDNA strands is
known to be more error prone than other polymerases, we
conclude that this TGA codon is an artefact of clone pB1. The
authentic termination codon found in clones pB2 and pB4 as
well as pB1 is located at the same position of exon 7 as in
HLA-B7 (10). No other nucleotide difference was found
among the sequenced insertions of the pB clones.
DISCUSSION
The predicted protein sequence of HLA-B27 antigen (Fig. 4)
has the known characteristics of an HLA heavy chain (1),
with conserved cysteine residues for the disulfide bridges of
the second (positions 101 and 164) and the third (positions 203
and 259) domains, and the single N-glycosylation site (posi-
tion 86). In the two external variable domains of the protein,
HLA-B27 displays the same degree of divergence from
HLA-B7 as from HLA-B40. Seeking possible structural
correlates of the unique features of this antigen it is interest-
ing to consider the position and the nature of the amino acid
replacements that distinguish HLA-B27 from other human
class I molecules. As expected, most of the amino acid
exchanges occur at positions or within segments responsible
for the variability of class I antigens (21, 23). Nevertheless,
seven unique positions can be recognized where HLA-B27
carries a residue not found in any of the HLA-A, -B, and -C
sequences comparable at present (Fig. 4). The replacements
at positions 70, 82, 83, 97, and 182 are unremarkable for they
either represent conservative substitutions or occupy sites of
intra- or interlocus variability. In contrast, two replacements
are unusual and deserve special comment. Position 67 is
occupied by a potentially reactive cysteine that might influ-
ence the intermolecular interactions of HLA-B27 due to its
location in an area thought to mediate the binding of mono-
clonal antibodies as well as of alloantibodies (22). However,
it is difficult to assess the relevance of such an amino acid
substitution in view of the observation that a free cysteine
occupies, for example, a similarly polymorphic site in the
HLA-Cw3 sequence (position 9). In contrast, the appearance
of a serine in position 131 is likely to have a more profound
effect on the conformation of HLA-B27, because this
nonconservative replacement occurs at a site invariably
occupied by a species-associated arginine residue in human
and lysine in mice (22). The species specificity of this residue
is confirmed in all murine class I gene sequences so far
known, which include H-2Kq, H-2Kwa (see ref. 24), Q8 and
Q 10 (BALB/c, see ref. 25), and Q 4-Q 10 (C57BL/10;
unpublished results); this position is occupied by an arginine
also in HLA-Aw24 (26) as well as in a rabbit class I antigen
(27). It is noteworthy that this site is embedded in segment
122-136, which defines an area submitted to stringent selec-
tive constraints because it represents the evolutionarily most
conserved region in the second domain of class I molecules.
As no secondary structure could be predicted for the segment
129-136 (28), it is impossible to guess what consequence the
replacement of a bulky polar residue by serine would have on
the tertiary structure of the antigen.
Our approach to clone HLA-B27 depended on the verifi-
cation of the postulate that the HLA-A,
-B, and -C allelic
series can indeed be recognized at the nucleotide and/or
protein level. In particular, the isolation of clone pC1 encod-
ing a protein whose incomplete sequence is essentially
superimposable to that deduced from HLA-Cw3, the only
HLA-C allele so far sequenced, allows us to make some
preliminary generalizations on the sequence markers diag-
nostic of each HLA locus. One such locus-specific trait
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FIG. 4. Alignment of the amino acid sequences predicted for HLA-B27 and -Cwl with otherHLA proteins. Partial sequences from nucleotide
data were completed with residues taken from protein data: B7 (21); B40 (22); A28 (21). Dashes indicate identity, asterisks mark positions
discussed in the text, and colons fill in gaps introduced to maximize matches. The one-letter code for amino acids is used. Residues distinctly
associated with each class I locus are shadowed.
resides in the different lengths of each mature HLA-A, -B,
and -C protein, which appear to be 341, 338, and 342 amino
acids long, respectively. Furthermore, several residues can
be easily discerned for their characteristic conservation
within each of the three sets of polypeptides (shadowed in
Fig. 4) or nucleotide sequences. It is noteworthy that these
diagnostic residues occur at positions differing among the
three allelic series. Evidently, they mark regions not affected
by recent events of intrachromosomal sequence exchanges,
of the type postulated to contribute to the generation of the
extraordinary polymorphism of class I genes (29). The
number of marker residues is notably higher in HLA-A and
HLA-C than in the HLA-B series. The HLA-B character of
the latter group is at the protein level practically confined to
the transmembrane and cytoplasmatic regions. This lack of
"B-ness" in the al and a2 domains is striking in comparison
to the 13 positions that in the same region are characteristic
of the HLA-A group. The discrepancy is unlikely due to a
biased sampling of serologically related sequences since both
sets of alleles include crossreactive antigens. It seems more
plausible that in this part of the molecule the HLA-B
character has been eroded by an extraordinary high level of
polymorphism combined with the clustering of variability
within the al and a2 domains of class I antigens (21, 23). If
additional data will bring to light intralocus subsets of
sequences more related to each other, this finding will
strengthen the suspicion that some of the presently defined
loci actually include pseudoallelic series (30).
A search for interlocus homologies shows that in the 3' UT
region the two HLA-C sequences share many nucleotide
matches with the HLA-B sequences at positions where the
HLA-As have instead a different and usually also invariant
residue (see Fig. 3). This high degree and pattern of similarity
is also evident at the amino acid level (7 matches over 39
positions are specifically common to the B/C sequences). It
will be interesting to extend the comparisons to introns and
flanking sequences to verify the indication that the HLA-B
and -C loci originated through a more recent gene duplica-
tion.
On the other hand, the sequence markers unique to
HLA-A, -B, and -C do not coincide with those specific for the
mouse H-2K, -D, and -L (13), thus providing strong evidence
that, in analogy with certain class III loci (31), the duplication
of class I genes occurred after the separation of the ancestors
of the two species. This conclusion is in accord with the
strong intraspecies conservation found in the introns of class
I genes (see refs. 16 and 25) as well as with the finding of an
amino acid gap in the region encoded by exon 7, which is
common to H-2K, D, and L and to the class I-related Q locus
but is not present in any of the human class I sequences (32).
In conclusion, HLA-B27 features two unique amino acid
substitutions that may critically affect the intermolecular
interactions of this antigen. It appears now crucial to deter-
mine whether these changes are common to the HLA-B27
subtypes defined by serological and biochemical (33, 34)
studies as well as by T-lymphocyte assays (35, 36), neither of
which shows a preferential correlation with AS. The finding
that these substitutions are conserved among the subtypes
would strengthen the relevance of these amino acids for the
major antigenic epitope(s) of HLA-B27 and as a molecular
site of correlation with the disease.
Alternatively, if a putative illness susceptibility gene in
linkage disequilibrium with HLA-B27 (with a coefficient of
0.019 according to ref. 4-i.e., about 90% of its possible
FIG. 3. Nucleotide sequence alignments of HLA-B27 and -Cwl in comparison with already reported HLA sequences. B7, partial cDNA
sequence (10); Cw3, genomic sequence (11); A, constructed by comparing the nucleotide sequences of three HLA-A genes: A3 (19), A2 (16),
and A28 (20); only matches common to the three sequences are reported, whereas variable positions are marked by asterisks. Nucleotides are
shown in triplets for coding regions and in blocks of 12 for the 3' UT. Dashes are used to indicate identity and colons are used to fill in gaps
introduced to maximize matches. The poly(A) signal is underlined. Numbered sites refer to codon positions of the processed polypeptide. Note
that the presence of an extra codon (2%/297) in HLA-C sequences coincides with the direct repeat of the nonanucleotide GCTGTCCTA.
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maximum) is responsible for the diseases associated with this
antigen (4, 5), the appearance of this mutation must have
predated the emergence ofthe HLA-B27 subtypes, as none of
them displays a stronger linkage disequilibrium with the
postulated "illness gene." If the recombination distance (r)
between the hypothetical gene and HLA-B27 were -
this linkage disequilibrium should have practically vanished
because of the decrement expected under Hardy-Weinberg
conditions of (1 - r) per generation and because the mutant
must be at least 25,000-100,000 years old-the time (i.e.,
1250-5000 generations) elapsed since the divergence of the
major human races (37). Furthermore, the frequency of 0.022
estimated for the AS susceptibility gene (4) suggests that,
according to the theoretical results obtained by Kimura and
Ohta (38), the mutant may be older and even as old as the life
span of the human species. Therefore, assuming an average
of 106 bp ofDNA per centimorgan (39), if such a susceptibility
gene does indeed exist, it should lie at most within a few
thousand base pairs from HLA-B27. This study has provided
the molecular basis for a direct test of the bacterial cross-
tolerance hypothesis for the HLA-B27 pathogenicity as well
as the structural data that can expedite the finding of the
postulated susceptibility locus contiguous to the HLA-B27
gene.
After this work was completed, Ezquerra et al. (40)
reported the sequence of a papain-solubilized HLA-B27
antigen. Their work conveys information on the primary
structure ofthe extracellular domains ofthe molecule, which,
except for an irrelevant change at position 182, is identical to
the one here deduced from the nucleotide sequence.
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